David D. Chism
YOU?
Author Swipe
View article: Machine learning to evaluate the effects of non-clinical social determinant features in predicting colorectal Cancer mortality in a medically underserved Appalachian population
Machine learning to evaluate the effects of non-clinical social determinant features in predicting colorectal Cancer mortality in a medically underserved Appalachian population Open
Colorectal cancer (CRC) is the 2nd leading cause of cancer death in the United States (US). Rural Appalachia suffers the highest CRC incidence and mortality rates. There are several non-clinical health-related social determinant factors (S…
View article: Obesity’s Disparate Impact on COVID-19 Outcomes in Asian American Patients with Cancer
Obesity’s Disparate Impact on COVID-19 Outcomes in Asian American Patients with Cancer Open
Data on COVID-19 outcomes in Asian Americans and Pacific Islanders (AAPI) are lacking. We analyzed data from 6,244 patients from the COVID-19 and Cancer Consortium, including 6.0% AAPI patients, to examine disparities in outcomes following…
View article: Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer
Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer Open
Importance: Non-Hispanic Black individuals experience a higher burden of COVID-19 than the general population; hence, there is an urgent need to characterize the unique clinical course and outcomes of COVID-19 in Black patients with cancer…
View article: Machine Learning to Evaluate the Effects of Non-Clinical Social Determinant Features in Predicting Colorectal Cancer Mortality in a Medically Underserved Appalachian Population
Machine Learning to Evaluate the Effects of Non-Clinical Social Determinant Features in Predicting Colorectal Cancer Mortality in a Medically Underserved Appalachian Population Open
Colorectal cancer (CRC) is the 2nd leading cause of cancer death in the United States (US). Rural Appalachia suffers the highest CRC incidence and mortality rates. There are several non-clinical health-related social determinant factors (S…
View article: Supplementary Table S10 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Supplementary Table S10 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma Open
Supplementary Table S10. Serum PK Parameters of Tab at Cycle 1, Day 15, PK Analysis Set
View article: Supplementary Table S3 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Supplementary Table S3 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma Open
Supplementary Table S3. SLITRK6 Expression Levels, H-Score: Parts A, B, and C, Expansion Phase (FAS)
View article: Supplementary Table S11 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Supplementary Table S11 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma Open
Supplementary Table S11. Statistical Assessment of Dose Proportionality for ADC, Power Model, PK Analysis Set
View article: Supplementary Figure S2 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Supplementary Figure S2 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma Open
Supplementary Figure S2. PFS, 1.00 mg/kg vs Total Study Population and CPIExposed Population (Parts A, B, and C, FAS)
View article: Supplementary Table S10 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Supplementary Table S10 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma Open
Supplementary Table S10. Serum PK Parameters of Tab at Cycle 1, Day 15, PK Analysis Set
View article: Supplementary Table S2 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Supplementary Table S2 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma Open
Supplementary Table S2. Representativeness of Study Participants
View article: Supplementary Table S8 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Supplementary Table S8 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma Open
Supplementary Table S8. Serum PK Parameters of MMAE at Cycle 1, Day 15, PK Analysis Set
View article: Supplementary Table S4 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Supplementary Table S4 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma Open
Supplementary Table S4. TEAEs (≥10% Patients) by SOC and PT: Part A, Escalation Phase
View article: Supplementary Table S9 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Supplementary Table S9 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma Open
Supplementary Table S9. Serum PK Parameters of TAb at Cycle 1, Day 1, PK Analysis Set
View article: Supplementary Table S1 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Supplementary Table S1 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma Open
Supplementary Table S1. Inclusion Criteria Details for Parts A, B, and C
View article: Supplementary Table S7 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Supplementary Table S7 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma Open
Supplementary Table S7. Serum PK Parameters of MMAE at Cycle 1, Day 1, PK Analysis Set
View article: Supplementary Table S6 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Supplementary Table S6 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma Open
Supplementary Table S6. Serum PK Parameters of AGS15E ADC at Cycle 1, Day 15, PK Analysis Set
View article: Supplementary Table S13 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Supplementary Table S13 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma Open
Supplementary Table S13. Statistical Assessment of Dose Proportionality for TAb, Power Model, PK Analysis Set
View article: Supplementary Table S1 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Supplementary Table S1 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma Open
Supplementary Table S1. Inclusion Criteria Details for Parts A, B, and C
View article: Supplementary Table S4 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Supplementary Table S4 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma Open
Supplementary Table S4. TEAEs (≥10% Patients) by SOC and PT: Part A, Escalation Phase
View article: Supplementary Table S14 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Supplementary Table S14 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma Open
Supplementary Table S14. BOR, ORR, and DCR With Confirmation; Part A, Escalation Phase
View article: Supplementary Figure S3 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Supplementary Figure S3 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma Open
Supplementary Figure S3. Box Plot of H-Score for SLITRK6 Expression in Tissue by Confirmed BOR (Full Analysis Set)
View article: Supplementary Table S5 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Supplementary Table S5 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma Open
Supplementary Table S5. Serum PK Parameters of AGS15E ADC at Cycle 1, Day 1 by Dose Group, PK Analysis Set
View article: Supplementary Table S12 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Supplementary Table S12 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma Open
Supplementary Table S12. Statistical Assessment of Dose Proportionality for MMAE, Power Model, PK Analysis Set
View article: Supplementary Table S9 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Supplementary Table S9 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma Open
Supplementary Table S9. Serum PK Parameters of TAb at Cycle 1, Day 1, PK Analysis Set
View article: Supplementary Figure S2 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Supplementary Figure S2 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma Open
Supplementary Figure S2. PFS, 1.00 mg/kg vs Total Study Population and CPIExposed Population (Parts A, B, and C, FAS)
View article: Supplementary Table S8 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Supplementary Table S8 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma Open
Supplementary Table S8. Serum PK Parameters of MMAE at Cycle 1, Day 15, PK Analysis Set
View article: Supplementary Table S6 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Supplementary Table S6 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma Open
Supplementary Table S6. Serum PK Parameters of AGS15E ADC at Cycle 1, Day 15, PK Analysis Set
View article: Supplementary Table S7 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Supplementary Table S7 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma Open
Supplementary Table S7. Serum PK Parameters of MMAE at Cycle 1, Day 1, PK Analysis Set
View article: Supplementary Figure S3 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Supplementary Figure S3 from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma Open
Supplementary Figure S3. Box Plot of H-Score for SLITRK6 Expression in Tissue by Confirmed BOR (Full Analysis Set)
View article: Data from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Data from Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma Open
Purpose:Effective treatment of locally advanced or metastatic urothelial carcinoma (mUC) remains an unmet need. Antibody–drug conjugates (ADC) providing targeted drug delivery have shown antitumor activity in this setting. AGS15E is an inv…